Apolipoprotein B/AI ratio is independently associated with non-alcoholic fatty liver disease in nondiabetic subjects

Journal of Gastroenterology and Hepatology (Australia)

Volumn 28, Issue 4, 2013, Pages 678-683

  Choe, Young Gil ^a   Jin, Wook ^b   Cho, Yong Kyun ^a   Chung, Won Gil ^a   Kim, Hong Joo ^a   Jeon, Woo Kyu ^a   Kim, Byung Ik ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b Gachon University   (South Korea)

Author keywords

ApoB AI ratio; Apolipoprotein; Non alcoholic fatty liver disease

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ATHEROSCLEROSIS; BODY HEIGHT; BODY WEIGHT; CARDIOVASCULAR RISK; CROSS-SECTIONAL STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ECHOGRAPHY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NONALCOHOLIC FATTY LIVER; OBESITY; PHYSICAL ACTIVITY; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 84875615668     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12077     Document Type: Article

References (28)

1. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 1221-1231.
2. Adams LA, Lymp JF, St Sauver J etal. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005; 129: 113-121.
3. Tsuneto A, Hida A, Sera N etal. Fatty liver incidence and predictive variables. Hypertens. Res. 2010; 33: 638-643.
4. Bugianesi E, Gastaldelli A, Vanni E etal. Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms. Diabetologia 2005; 48: 634-642.
5. Marchesini G, Bugianesi E, Forlani G etal. Non-alcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 2003; 37: 917-923.
6. Choi SY, Kim D, Kim HJ etal. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am. J. Gastroenterol. 2009; 104: 1953-1960.
7. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N. Engl. J. Med. 2010; 363: 1341-1350.
8. Walldius G, Jungner I. Apolipoprotein B and apolipoprotein AI: risk indicators of coronary heart disease and targets for lipid-modifying therapy. J. Intern. Med. 2004; 255: 188-205.
9. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026-2033.
10. Genest J Jr, McNamara JR, Ordovas JM etal. Lipoprotein cholesterol, apolipoprotein A-I and B and lipoprotein (a) abnormalities in men with premature coronary artery disease. J. Am. Coll. Cardiol. 1992; 19: 792-802.
11. Sniderman AD, Furberg CD, Keech A etal. Apolipoproteins versus lipids as indices of coronary risk and as targets for statin treatment. Lancet 2003; 361: 777-780.
12. Yusuf S, Hawken S, Ounpuu S etal. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
13. Vaessen SF, Schaap FG, Kuivenhoven JA etal. Apolipoprotein A-V, triglycerides and risk of coronary artery disease: the prospective Epic-Norfolk Population Study. J. Lipid Res. 2006; 47: 2064-2070.
14. Dunder K, Lind L, Zethelius B, Berglund L, Lithell H. Evaluation of a scoring scheme, including proinsulin and the apolipoprotein B/apolipoprotein AI ratio, for the risk of acute coronary events in middle-aged men: Uppsala Longitudinal Study of Adult Men (ULSAM). Am. Heart J. 2004; 148: 596-601.
15. Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur. Heart J. 2005; 26: 271-278.
16. Thompson A, Danesh J. Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J. Intern. Med. 2006; 259: 481-492.
17. Sierra-Johnson J, Somers VK, Kuniyoshi FH etal. Comparison of apolipoprotein-B/apolipoprotein-AI in subjects with versus without the metabolic syndrome. Am. J. Cardiol. 2006; 98: 1369-1373.
18. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet. Med. 2006; 23: 469-480.
19. Saadeh S, Younossi ZM, Remer EM etal. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002; 123: 745-750.
20. Hewitt KN, Pratis K, Jones ME, Simpson ER. Estrogen replacement reverses the hepatic steatosis phenotype in the male aromatase knockout mouse. Endocrinology 2004; 145: 1842-1848.
21. Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology 2002; 122: 1649-1657.
22. Nishino M, Hayakawa K, Nakamura Y etal. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: high frequency of involvement and rapid reversal after completion of tamoxifen therapy. AJR Am. J. Roentgenol. 2003; 180: 129-134.
23. Sung KC, Ryan MC, Wilson AM. The severity of nonalcoholic fatty liver disease is associated with increased cardiovascular risk in a large cohort of non-obese Asian subjects. Atherosclerosis 2009; 203: 581-586.
24. Musso G, Gambino R, Bo S etal. Should nonalcoholic fatty liver disease be included in the definition of metabolic syndrome? A cross-sectional comparison with Adult Treatment Panel III criteria in nonobese nondiabetic subjects. Diabetes Care 2008; 31: 562-568.
25. Musso G, Gambino R, De Michieli F etal. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003; 37: 909-916.
26. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J. Clin. Gastroenterol. 2006; 40 (Suppl. 1): S17-29.
27. Matsuzawa Y, Funahashi T, Kihara S, Shimomura I. Adiponectin and metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 2004; 24: 29-33.
28. Charlton M, Sreekumar R, Rasmussen D, Lindorin K, Nair KS. Apolipoprotein synthesis in nonalcoholic steatohepatitis. Hepatology 2002; 35: 898-904.